BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Dec. 10, 2003
View Archived Issues
Actelion, Merck Enter Oral Renin Inhibitor Pact Worth Up To $272M
Swiss biopharmaceutical firm Actelion Ltd. added $10 million to its cash pile, on the strength of an exclusive alliance with Merck & Co. Inc. in the area of oral renin inhibitors. (BioWorld International)
Read More
Europe Fumbles Two Major Biotech-Related Decisions
Read More
'Reverse Vaccination' Might Help Stop Unwanted Immune Response
Read More
Clinical Trials Could Become More Difficult For Small Firms
Read More
PPL On The Block; Dolly's Creator Fades Into History
Read More
Cyclacel In-Licenses Cancer Compound From Sankyo Co.
Read More
Bavarian Nordic Investing In Production Facility, R&D
Read More
Stockholm Planning Bioscience Hub; Funding Concerns Remain
Read More
French Food Safety Agency Has Bt11 Sweet Corn Doubts
Read More
Other News To Note
Read More